Please select a country

Subject Matter Experts

PharmaLex stands for PHLEXibility! We are a passionate team of over 650 people from more than 40 nationalities with a unique blend of dedicated experts. Our diversity provides a distinct advantage in an era when flexibility and creativity are key to competitiveness.

Each month we will focus on just a few of our key experts. Make sure to check back regularly to who’s next in focus!

Our subject matter experts also host educational webinars. Check out the latest one here >>

Andrew Verderame

President, PharmaLex US

Anti-infective expect

Andrew has over 30 years experience in pharma. He has led over two hundred meetings with FDA, managed multi-site regulatory teams, and has presented to FDA Advisory Committees with successful outcomes.

Zeb Younes

Associate Director, Regulatory Affairs at PharmaLex UK

Biosimilars expert

Zeb’s experience lies in biosimilar development from proof of concept through to commercialization. She has worked with ATMPs, vaccines, recombinant proteins & derivatives as well as many biosimilar products.

Adair Turner

Principal Consultant, Director of Regulatory Operations, PharmaLex US

INDs expert

Adair has a wealth of experience in managing hundreds of Regulatory submissions throughout the product lifecycle, leading cross-functional project teams, and implementing innovative technologies.

Patrick Larcier

Senior Director Drug Development & Vigilance, PharmaLex France

ATUs expert

Patrick is an expert in the design & implementation of regulatory strategies during clinical development for complex & innovative medicinal products, contact with EU Regulatory Agencies, co-development of IVDs & drugs.